These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36780987)

  • 21. Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial.
    Krajden M; Cook D; Yu A; Chow R; Su Q; Mei W; McNeil S; Money D; Dionne M; Palefsky J; Karunakaran K; Kollmann T; Ogilvie G; Petric M; Dobson S
    Vaccine; 2014 Jan; 32(5):624-30. PubMed ID: 24055350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mixed Bacteriophage MS2-L2 VLPs Elicit Long-Lasting Protective Antibodies against HPV Pseudovirus 51.
    Yadav R; Zhai L; Kunda NK; Muttil P; Tumban E
    Viruses; 2021 Jun; 13(6):. PubMed ID: 34200586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single-dose HPV vaccine immunity: is there a role for non-neutralizing antibodies?
    Quang C; Chung AW; Frazer IH; Toh ZQ; Licciardi PV
    Trends Immunol; 2022 Oct; 43(10):815-825. PubMed ID: 35995705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques.
    Nieto K; Stahl-Hennig C; Leuchs B; Müller M; Gissmann L; Kleinschmidt JA
    Hum Gene Ther; 2012 Jul; 23(7):733-41. PubMed ID: 22401308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the thermal stability and the protective efficacy of spray-dried HPV vaccine, Gardasil® 9.
    Kunda NK; Peabody J; Zhai L; Price DN; Chackerian B; Tumban E; Muttil P
    Hum Vaccin Immunother; 2019; 15(7-8):1995-2002. PubMed ID: 30883270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prophylactic DNA immunization against multiple papillomavirus types.
    Gasparić M; Rubio I; Thönes N; Gissmann L; Müller M
    Vaccine; 2007 Jun; 25(23):4540-53. PubMed ID: 17485151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sublingual immunization of trivalent human papillomavirus DNA vaccine in baculovirus nanovector for protection against vaginal challenge.
    Lee HJ; Cho H; Kim MG; Heo YK; Cho Y; Gwon YD; Park KH; Jin H; Kim J; Oh YK; Kim YB
    PLoS One; 2015; 10(3):e0119408. PubMed ID: 25789464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11.
    Smith JF; Kowalski R; Esser MT; Brown MJ; Bryan JT
    Hum Vaccin; 2008; 4(2):134-42. PubMed ID: 18388490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14 years: Results to month 36 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HML; Lee BW; Rombo L; Tan NC; Rouzier R; De Simoni S; Suryakiran P; Hezareh M; Thomas F; Folschweiller N; Struyf F
    Vaccine; 2018 Jan; 36(1):98-106. PubMed ID: 29174109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice.
    Chen X; Zhang T; Liu H; Hao Y; Liao G; Xu X
    Hum Vaccin Immunother; 2018; 14(8):2025-2033. PubMed ID: 29683766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A human papillomavirus type 16 vaccine by oral delivery of L1 protein.
    Sasagawa T; Tani M; Basha W; Rose RC; Tohda H; Giga-Hama Y; Azar KK; Yasuda H; Sakai A; Inoue M
    Virus Res; 2005 Jun; 110(1-2):81-90. PubMed ID: 15845258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.
    Harro CD; Pang YY; Roden RB; Hildesheim A; Wang Z; Reynolds MJ; Mast TC; Robinson R; Murphy BR; Karron RA; Dillner J; Schiller JT; Lowy DR
    J Natl Cancer Inst; 2001 Feb; 93(4):284-92. PubMed ID: 11181775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rectal and vaginal immunization of mice with human papillomavirus L1 virus-like particles.
    Fraillery D; Zosso N; Nardelli-Haefliger D
    Vaccine; 2009 Apr; 27(17):2326-34. PubMed ID: 19428847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical study of safety and immunogenicity of combined rubella and human papillomavirus vaccines: Towards enhancing vaccination uptake rates in developing countries.
    Gohar A; Abdeltawab NF; Shehata N; Amin MA
    Papillomavirus Res; 2019 Dec; 8():100172. PubMed ID: 31185296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial.
    Toft L; Storgaard M; Müller M; Sehr P; Bonde J; Tolstrup M; Østergaard L; Søgaard OS
    J Infect Dis; 2014 Apr; 209(8):1165-73. PubMed ID: 24273179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes.
    Kalnin K; Tibbitts T; Yan Y; Stegalkina S; Shen L; Costa V; Sabharwal R; Anderson SF; Day PM; Christensen N; Schiller JT; Jagu S; Roden RB; Almond J; Kleanthous H
    Vaccine; 2014 Jun; 32(28):3540-7. PubMed ID: 24780250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection.
    Jagu S; Kwak K; Garcea RL; Roden RB
    Vaccine; 2010 Jun; 28(28):4478-86. PubMed ID: 20434552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.
    Reisinger KS; Block SL; Lazcano-Ponce E; Samakoses R; Esser MT; Erick J; Puchalski D; Giacoletti KE; Sings HL; Lukac S; Alvarez FB; Barr E
    Pediatr Infect Dis J; 2007 Mar; 26(3):201-9. PubMed ID: 17484215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human papillomavirus L1 protein expressed in Escherichia coli self-assembles into virus-like particles that are highly immunogenic.
    Chen Y; Liu Y; Zhang G; Wang A; Dong Z; Qi Y; Wang J; Zhao B; Li N; Jiang M
    Virus Res; 2016 Jul; 220():97-103. PubMed ID: 27107614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.